Engineering a Pathway to Glucose-Responsive Therapeutics

Diabetes. 2024 Jul 1;73(7):1032-1038. doi: 10.2337/dbi23-0029.

Abstract

In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes program. This program took a multifaceted approach to providing key funding to diabetes researchers to advance a broad spectrum of research programs on all aspects of understanding, managing, and treating diabetes. Here, the personal perspective of a 2019 Pathway Accelerator awardee is offered, describing a research program seeking to advance a materials-centered approach to engineering glucose-responsive devices and new delivery tools for better therapeutic outcomes in treating diabetes. This is offered alongside a personal reflection on 5 years of support from the ADA Pathway Program.

Publication types

  • Review

MeSH terms

  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus* / drug therapy
  • Diabetes Mellitus* / therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use

Substances

  • Blood Glucose
  • Hypoglycemic Agents